Acutus Medical Reports Third Quarter and Year-To-Date 2024 Financial Results

This post was originally published on this site

Share this story

CARLSBAD, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) — Acutus Medical, Inc. (“Acutus” or the “Company”) (OTC: AFIB) today reported results for the third quarter and year-to-date of 2024.

Recent Highlights:

  • Third quarter revenue from Continuing Operations of $5.3 million grew 156% year-over-year, from $2.1 million in the same quarter last year.
  • Operating income for continuing operations was $0.1 million, an improvement of 119% compared to the same period last year.
  • Recorded $2.4 million in gain on sale of business, a decrease of 8% compared to the same period last year.
  • Cash, cash equivalents, marketable securities and restricted cash were $12.6 million as of September 30, 2024.

Third Quarter 2024 Financial Results
Revenue from Continuing Operations was $5.3 million for the third quarter of 2024, an increase of 156% compared to $2.1 million for the third quarter of 2023.

Gross margin on a GAAP basis for continuing operations was 7% for the third quarter of 2024 compared to negative 53% for the same quarter last year. The improvement was driven by higher production volumes related to left-heart access manufacturing and reduced manufacturing overhead expenses.

Operating income for continuing operations on a GAAP basis was $0.1 million for the third quarter of 2024 compared to Operating expenses of $0.6 million for the same period last year. The decrease in operating expenses from reduced discretionary spend under this new business model.

Net loss on continuing operations on a GAAP basis was $0.8 million for the third quarter of 2024 and net loss per share was $0.03 on a weighted average basic and diluted outstanding share count of 29.8 million, compared to a net loss of $1.9 million and a net loss per share of $0.7 on a weighted average basic and diluted outstanding share count of 29.3 million for the same period last year.

Cash, cash equivalents, marketable securities and restricted cash were $12.6 million as of September 30, 2024.

Loss on Discontinued Operations
Loss on discontinued operations was $4.8 million for third quarter of 2024, compared to $13.2 million for the same period last year.

Outlook
Due to the announced plan to realign resources to support the left-heart access distribution business and exit from the electrophysiology mapping and ablation businesses, the Company will no longer provide financial guidance.

About Acutus
Acutus is focused on the production of left-heart access products under its distribution agreement with Medtronic, Inc. Founded in 2011, Acutus is based in Carlsbad, California.

Caution Regarding Forward-Looking Statements
This press release includes statements that may constitute “forward-looking” statements, usually containing the words ‘believe”, “estimate”, “project”, “expect” or similar expressions. Forward looking statements inherently involve risks and uncertainties that could cause actual results to differ materially from forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to continue to manage expenses and cash burn rate at sustainable levels, successful completion of the Company’s restructuring plan, continued acceptance of the Company’s left-heart access products in the marketplace, the effect of global economic conditions on the ability and willingness of Medtronic to purchase the Company’s left-heart access products and the timing of such purchases, competitive factors, changes resulting from healthcare policy in the United States and globally including changes in government reimbursement of procedures, dependence upon third-party vendors and distributors, timing of regulatory approvals, the Company’s ability to maintain its listing on Nasdaq, and other risks discussed in the Company’s periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, Acutus undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Investor Contact:
Chad Hollister
Acutus Medical, Inc.
investors@acutus.com

Acutus Medical, Inc.
Consolidated Balance Sheets
September 30,
2024
December 31,
2023
(in thousands, except share and per share amounts) (unaudited)
ASSETS
Current assets:
Cash and cash equivalents $ 12,595 $ 19,170
Marketable securities, short-term 3,233
Restricted cash, short-term 7,030
Accounts receivable 9,970 11,353
Inventory 4,191 4,278
Prepaid expenses and other current assets 403 678
Current assets of discontinued operations (Note 3) 510
Total current assets 27,159 46,252
Property and equipment, net 736 825
Right-of-use assets, net 2,647 3,189
Other assets 94 94
Non-current assets of discontinued operations (Note 3) 1,531 3,600
Total assets $ 32,167 $ 53,960
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable 1,711 2,761
Accrued liabilities 1,702 2,887
Operating lease liabilities, short-term 897 718
Long-term debt, current portion 7,084 1,864
Warrant liability 302 409
Current liabilities of discontinued operations (Note 3) 2,969 10,303
Total current liabilities 14,665 18,942
Operating lease liabilities, long-term 2,532 3,243
Long-term debt 25,269 32,654
Total liabilities 42,466 54,839
Commitments and contingencies (Note 11)
Stockholders’ deficit
Preferred stock, $0.001 par value; 5,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 6,666 shares of preferred stock, designated as Series A Common Equivalent Preferred Stock, are issued and outstanding as of September 30, 2024 and December 31, 2023
Common stock, $0.001 par value; 260,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 29,912,305 and 29,313,667 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 30 29
Additional paid-in capital 598,670 599,935
Accumulated deficit (608,118 ) (599,977 )
Accumulated other comprehensive loss (881 ) (866 )
Total stockholders’ deficit (10,299 ) (879 )
Total liabilities and stockholders’ deficit $ 32,167 $ 53,960
Acutus Medical, Inc.
Consolidated Statements of Operations and Comprehensive Loss
Three Months Ended September 30, Nine Months Ended September 30,
2024 2023 2024 2023
(in thousands, except share and per share amounts) (unaudited)
Revenue $ 5,266 $ 2,060 $ 13,027 $ 4,816
Cost of products sold 4,894 3,150 13,019 7,835
Gross profit (loss) 372 (1,090 ) 8 (3,019 )
Operating expenses (income):
Research and development 896 2,752
Selling, general and administrative 2,318 2,354 7,880 9,502
Change in fair value of contingent consideration 123
Gain on sale of business (2,435 ) (2,648 ) (8,096 ) (5,927 )
Total operating expenses (income) (117 ) 602 (216 ) 6,450
Gain (loss) from operations 489 (1,692 ) 224 (9,469 )
Other income (expense):
Change in fair value of warrant liability (174 ) 636 107 1,478
Interest income 153 547 641 2,223
Interest expense (1,395 ) (1,409 ) (4,384 ) (4,110 )
Other revenue 111 187
Total other expense, net (1,305 ) (226 ) (3,449 ) (409 )
Loss from continuing operations before income taxes (816 ) (1,918 ) (3,225 ) (9,878 )
Net loss from continuing operations (816 ) (1,918 ) (3,225 ) (9,878 )
Discontinued operations:
Loss from discontinued operations before taxes (4,791 ) (11,244 ) (4,906 ) (37,945 )
Income tax expense – discontinued operations 75 10 75
Net loss from discontinued operations (4,791 ) (11,319 ) (4,916 ) (38,020 )
Net loss $ (5,607 ) $ (13,237 ) $ (8,141 ) $ (47,898 )
Other comprehensive loss
Unrealized loss (gain) on marketable securities 4 7
Foreign currency translation adjustment (15 ) (66 ) (15 ) (91 )
Comprehensive loss $ (5,622 ) $ (13,299 ) $ (8,156 ) $ (47,982 )
Net loss per share, basic and diluted:
Loss from continuing operations $ (0.03 ) $ (0.07 ) $ (0.11 ) $ (0.34 )
Loss from discontinued operations $ (0.16 ) $ (0.39 ) $ (0.17 ) $ (1.31 )
Net loss per common share $ (0.19 ) $ (0.45 ) $ (0.27 ) $ (1.65 )
Weighted average shares outstanding, basic and diluted 29,799,241 29,262,768 29,768,208 29,024,353
Acutus Medical, Inc.
Consolidated Statements of Cash Flows
Nine Months Ended September 30,
2024 2023
(in thousands) (unaudited)
Cash flows from operating activities
Net loss $ (8,141 ) $ (47,898 )
Less: Loss from discontinued operations 4,916 38,020
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation expense 235 384
Non-cash stock-based compensation expense 459 1,272
Accretion of discounts on marketable securities, net (28 ) (1,318 )
Amortization of debt issuance costs 460 325
Amortization of operating lease right-of-use assets 542 513
Gain on sale of business, net (8,096 ) (5,927 )
Change in fair value of warrant liability (107 ) (1,478 )
Loss on disposal of property and equipment
Change in fair value of contingent consideration 123
Changes in operating assets and liabilities:
Accounts receivable (3,499 ) 3,247
Inventory 87 11,567
Employer retention credit receivable 4,703
Prepaid expenses and other current assets 286 2,010
Accounts payable (1,050 ) (3,020 )
Accrued liabilities (1,442 ) (8,043 )
Operating lease liabilities (532 ) (253 )
Other long-term liabilities 20
Net cash used in operating activities – continuing operations (15,910 ) (5,753 )
Net cash used in operating activities – discontinued operations (11,692 ) (39,352 )
Net cash used in operating activities (27,602 ) (45,105 )
Cash flows from investing activities
Proceeds from sale of business 13,235 17,000
Purchases of available-for-sale marketable securities (38,521 )
Sales of available-for-sale marketable securities 500
Maturities of available-for-sale marketable securities 2,750 70,250
Purchases of property and equipment (148 ) (1,187 )
Net cash provided by investing activities – continuing operations 16,337 47,542
Net cash provided by (used in) investing activities – discontinued operations 339 (207 )
Net cash provided by investing activities 16,676 47,335
Cash flows from financing activities
Repayment of debt (2,625 )
Proceeds from the exercise of stock options 4
Repurchase of common shares to pay employee withholding taxes (35 )
Proceeds from employee stock purchase plan 25
Net cash (used in) provided by financing activities – continuing operations (2,625 ) (1,929 )
Net cash used in financing activities – discontinued operations (41 ) (240 )
Net cash used in financing activities (2,666 ) (2,169 )
Effect of exchange rate changes on cash, cash equivalents and restricted cash (13 ) (294 )
Net change in cash, cash equivalents and restricted cash (13,605 ) (233 )
Cash, cash equivalents and restricted cash, at the beginning of the period 26,200 31,348
Cash, cash equivalents and restricted cash, at the end of the period $ 12,595 $ 31,115
Supplemental disclosure of cash flow information:
Cash paid for interest 3,394 3,731
Supplemental disclosure of noncash investing and financing activities:
Accounts receivable from sale of business $ 4,478 $ 6,111
Change in unrealized (gain) on marketable securities $ $ (7 )
Change in unpaid purchases of property and equipment $ $ 35

image

Comments are closed.